S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

Covetrus Stock Price, Forecast & Analysis (NASDAQ:CVET)

$13.69
+1.43 (+11.66 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$12.23
Now: $13.69
$13.90
50-Day Range
$8.80
MA: $10.64
$12.78
52-Week Range
$8.16
Now: $13.69
$43.83
Volume5.54 million shs
Average Volume1.87 million shs
Market Capitalization$1.53 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:CVET
CUSIPN/A
CIKN/A
Phone888-280-2221

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.78 billion

Profitability

Miscellaneous

Employees5,000
Market Cap$1.53 billion
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.


Covetrus (NASDAQ:CVET) Frequently Asked Questions

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

How were Covetrus' earnings last quarter?

Covetrus Inc (NASDAQ:CVET) announced its quarterly earnings results on Tuesday, November, 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.09. The firm earned $1.02 billion during the quarter, compared to the consensus estimate of $963.69 million. Covetrus's revenue was up 10.3% on a year-over-year basis. View Covetrus' Earnings History.

When is Covetrus' next earnings date?

Covetrus is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Covetrus.

What price target have analysts set for CVET?

8 equities research analysts have issued 12 month price targets for Covetrus' stock. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' share price to reach $15.25 in the next year. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Price Targets for Covetrus.

What is the consensus analysts' recommendation for Covetrus?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Covetrus.

Has Covetrus been receiving favorable news coverage?

News stories about CVET stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Covetrus earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Covetrus.

Are investors shorting Covetrus?

Covetrus saw a increase in short interest in October. As of October 31st, there was short interest totalling 13,100,000 shares, an increase of 12.2% from the September 30th total of 11,680,000 shares. Based on an average trading volume of 2,050,000 shares, the days-to-cover ratio is currently 6.4 days. Approximately 13.5% of the shares of the company are sold short. View Covetrus' Current Options Chain.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include IDEXX Laboratories (IDXX), Baidu (BIDU), Alphabet (GOOG), Kraft Heinz (KHC), Evolent Health (EVH), Nokia Oyj (NOK), Koninklijke DSM (DSM), LVMH Moet Hennessy Louis Vuitton (MC), Aimmune Therapeutics (AIMT) and bluebird bio (BLUE).

Who are Covetrus' key executives?

Covetrus' management team includes the folowing people:
  • Benjamin J. Shaw, President, Chief Executive Officer & Director
  • Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
  • Matthew Leonard, Executive VP & President-North America
  • Jim Young, Chief Human Resources Officer & Senior VP
  • Erin Powers Brennan, Secretary, Senior Vice President & General Counsel

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (1.41%), Great West Life Assurance Co. Can (0.87%), Alecta Pensionsforsakring Omsesidigt (0.56%), Gabelli Funds LLC (0.38%), TimesSquare Capital Management LLC (0.26%) and Rhumbline Advisers (0.21%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View Institutional Ownership Trends for Covetrus.

Which institutional investors are buying Covetrus stock?

CVET stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Great West Life Assurance Co. Can, Alecta Pensionsforsakring Omsesidigt, Gabelli Funds LLC, TimesSquare Capital Management LLC, Rhumbline Advisers, Gamco Investors INC. ET AL and California Public Employees Retirement System. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw and Erin Powers Brennan. View Insider Buying and Selling for Covetrus.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $13.69.

How big of a company is Covetrus?

Covetrus has a market capitalization of $1.53 billion and generates $3.78 billion in revenue each year. Covetrus employs 5,000 workers across the globe.View Additional Information About Covetrus.

What is Covetrus' official website?

The official website for Covetrus is http://www.henryscheinvet.com/.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]


MarketBeat Community Rating for Covetrus (NASDAQ CVET)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  165
MarketBeat's community ratings are surveys of what our community members think about Covetrus and other stocks. Vote "Outperform" if you believe CVET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVET will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel